MorphoSys AG (MPSYY.PK) reported promising pre-clinical data on its proprietary drug candidate MOR208, a potent anti-CD19 antibody with a proprietary modification to the Fc portion that is being developed to treat B-cell malignancies. The pre-clinical data, which would be presented at the Annual Meeting of the American Society of Clinical Oncology on June 4, 2012, illustrate the potential for four different combination therapies with MOR208in models of lymphoma.
The company added, "These intriguing results provide a first rationale for MOR208 drug combinations which warrant further evaluation in clinical trials." MOR208 is an Fc-engineered, humanized, anti-CD19 antibody with superior cytotoxicity in a number of in vitro and in vivo models of lymphoma and leukemia.
In June 2010, MorphoSys AG and Xencor reached a collaboration deal, which provided MorphoSys with an exclusive worldwide license to MOR208.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.